In our analysis of the CRC cohort in TCGA, we found that high PLOD3 expression was significantly associated with poor survival of patients, and PLOD3 was negatively correlated with the immune cells infiltrating in TME. The gene discussed is PLOD3; the disease is colorectal carcinoma.